NASDAQ$MMSI

Merit Medical Systems Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Merit Medical experienced a revenue decline but demonstrated progress in strategic goals and free cash flow generation.

Merit Medical reported a decrease in revenue for Q2 2020, with a worldwide revenue of $218.4 million, a (14.5)% decrease compared to Q2 2019. The company reported a GAAP loss per share of $(0.34) and a non-GAAP EPS of $0.31. Despite the revenue decline, the company generated $32 million in free cash flow and continued progress on strategic goals.

  • Worldwide revenue decreased by (14.5)% to $218.4 million compared to Q2 2019.
  • Core revenue on a constant currency basis decreased by (13.6)% compared to Q2 2019.
  • GAAP loss per share was $(0.34), compared to GAAP EPS of $0.12 in Q2 2019.
  • Non-GAAP EPS was $0.31, compared to $0.42 in Q2 2019.

Headline financials

Total Revenue

$218M

Previous: $256M-14.5%
EPS (adj)

$0.31

Previous: $0.42-26.2%
GAAP Operating Margin

-8.7%

No prior period
Non-GAAP Operating Margin

11.2%

No prior period
Capital Expenditures

-$25.8M

Previous: -$36M+28.2%
Free Cash Flow

-$44.9M

Previous: -$29.1M-54.2%
Net Income

-$19.1M

Previous: $6.86M-377.9%
Operating Income

-$19M

Previous: $12.2M-255.7%
Gross Profit

$84.2M

Previous: $112M-24.8%
Cash & Equivalents

$49.7M

Previous: $35.2M+41.3%
Total Assets

$1.72B

Previous: $1.74B-1.2%
Stock-Based Comp

$3.43M

Previous: $2.52M+35.9%

Revenue & EPS history

Merit Medical · Revenue · Quarterly

$218M

Q2 2020-14.5%vs Q2 2019
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Merit Medical · $6.19M total across 1 segment · Q2 2020

  • Endoscopy
    $6.19M-30.1%

Forward guidance

Due to the general uncertainty and rapidly changing global environment related to the COVID-19 pandemic and corresponding economic downturn, Merit’s management has concluded that it cannot issue financial guidance for the remainder of 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

-0.1%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+1.8%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+16.5%

Q3 2014

Best reaction

-31.4%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.2%-6.8%-2.8%
Q4 2025-3.8%-7.2%-16.6%
Q3 2025+5.1%+4.9%+4.3%
Q1 2025-0.1%-0.2%+0.7%
Q4 2024-1.5%+1.0%+1.9%
Q3 2024+2.9%+3.3%+8.3%
Q2 2024+4.0%+5.0%+13.4%
Q1 2024+2.1%+5.2%+7.8%
Q4 2023-5.3%-4.9%-5.9%
Q3 2023+7.7%+7.3%+12.9%
Q2 2023-9.6%-8.3%-16.4%
Q1 2023+4.7%+5.1%+4.3%
Q4 2022+2.8%+1.3%+3.7%
Q3 2022+7.0%+14.6%+19.6%
Q2 2022+6.0%+10.6%+10.0%
Q1 2022-3.7%-4.7%-5.2%
Q4 2021+8.4%+9.3%+5.0%
Q3 2021-1.8%-5.1%-3.5%
Q2 2021+7.6%+3.9%+10.1%
Q1 2021-0.2%+1.4%-5.3%
Q4 2020-1.8%-0.4%+1.9%
Q3 2020+5.2%+1.3%+11.7%
Q2 2020+4.3%-1.9%+11.6%
Q1 2020+9.0%+6.5%+21.4%
Q4 2019+0.4%-9.5%-17.0%
Q3 2019-31.4%-15.5%-7.0%
Q2 2019-24.7%-26.2%-37.2%
Q1 2019-1.9%-4.7%-9.4%
Q4 2018-4.3%-2.1%+1.6%
Q3 2018-4.1%-5.3%-3.5%
Q2 2018+2.8%-3.1%+3.3%
Q1 2018+2.8%+7.5%+18.7%
Q4 2017-2.1%-5.1%-3.3%
Q3 2017-9.7%-11.0%+4.6%
Q2 2017+4.8%+5.5%+4.6%
Q1 2017+8.2%+8.2%+11.6%
Q4 2016+5.9%+4.8%+0.0%
Q3 2016-5.0%-5.0%+5.2%
Q2 2016+6.1%+6.7%+6.5%
Q1 2016+2.5%
Q4 2015-2.8%
Q3 2015-27.3%
Q2 2015+10.7%
Q1 2015+9.5%
Q4 2014+7.7%
Q3 2014+16.5%
Q2 2014-14.4%
Q1 2014-5.4%
Q4 2013+1.2%
Q3 2013+15.4%
Q2 2013+7.6%
Q1 2013-13.9%
Q4 2012-14.7%
Q3 2012-2.8%
Q2 2012-0.5%
Q1 2011-0.7%
Q4 2011-0.7%
Q1 2012+1.1%
Q1 2010-1.6%
Q4 2009-1.6%
Q3 2010-1.1%
Q3 2011-1.1%
Q2 2011+1.6%
Q2 2010+1.6%
Q4 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro